

DAFTAR PUSTAKA

- Ahrens, I., Bode, C., & Zirlik, A. (2014). *Anticoagulation during and after acute coronary syndrome*. 1–6. <https://doi.org/10.5482/HAMO-13-09-0048>
- Alfonso, J., Terres, R., Kendall, R., & Sculpher, M. J. (2015). *Cost-effectiveness of fondaparinux versus enoxaparin in non-ST-elevation acute coronary syndrome in Canada (OASIS-5)*. *BMC Cardiovascular Disorders*, 1–6. <https://doi.org/10.1186/s12872-015-0175-1>
- Alhassan, S. M., Ahmed, H. G., Almutlaq, B. A., Alshammari, R. K., Alshammari, K. T., Alshammari, H. A., Almubrad, J. I., Alturkistani, H., Turkustani, M. Z., & Alsabban, A. H. (2017). *Risk Factors Associated with Acute Coronary Syndrome in Northern Saudi Arabia*. 8(3). <https://doi.org/10.15406/jccr.2017.08.00281>
- Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., Levine, G. N., Liebson, P. R., Mukherjee, D., Peterson, E. D., Sabatine, M. S., Smalling, R. W., Zieman, S. J., Anderson, J. L., Halperin, J. L., ... Yancy, C. W. (2014). *2014 AHA/ACC guideline for the management of patients with non-st-elevation acute coronary syndromes: A report of the American college of cardiology/American heart association task force on practice guidelines*. In *Circulation* (Vol. 130, Issue 25). <https://doi.org/10.1161/CIR.0000000000000134>
- Anderson, J. A. M., Hirsh, J., Yusuf, S., Johnston, M., & Mehta, S. R. (2010). *Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the organization to assess strategies in acute ischemic syndromes (OASIS) -5 trial*. 243–249. <https://doi.org/10.1111/j.1538-7836.2009.03705.x>
- Brito, V., Ciapponi, A., & Kwong, J. (2011). *Factor Xa inhibitors for acute coronary syndromes*. *Cochrane Database of Systematic Reviews*, 3. <https://doi.org/10.1002/14651858.cd007038.pub2>
- Bundhun, P. K., Shaik, M., & Yuan, J. (2017). *Choosing between Enoxaparin and Fondaparinux for the management of patients with acute coronary syndrome : A systematic review and meta-analysis*. 1–13. <https://doi.org/10.1186/s12872-017-0552-z>
- Cimci, M., Gencer, B., & Roffi, M. (2018). *Non-ST-Elevation Myocardial Infarction: Management*. In *Encyclopedia of Cardiovascular Research and Medicine*. Elsevier Inc. <https://doi.org/10.1016/b978-0-12-809657-4.99747-3>
- Dai, X., Busby-Whitehead, J., & Alexander, K. P. (2016). *Acute coronary syndrome in the older adults*. *Journal of Geriatric Cardiology*, 13(2), 101–108. <https://doi.org/10.11909/j.issn.1671-5411.2016.02.012>

- De Silva, K., Perera, D., & O’Kane, P. (2018). *Acute myocardial infarction: STEMI and NSTEMI*. In *Cardiovascular Thrombus: From Pathology and Clinical Presentations to Imaging, Pharmacotherapy and Interventions*. Elsevier Inc. <https://doi.org/10.1016/B978-0-12-812615-8.00009-0>
- Deven J. Patel, Knight, C. J., Holdright, D. R., Mulcahy, D., Clarke, D., Wright, C., Henry Purcell, A., & Fox, K. M. (1997). *Pathophysiology of Transient Myocardial Ischemia in Acute Coronary Syndromes*. American Heart Association. <https://doi.org/10.1177/0885066697011005000016>
- dos Santos, E. S., Baltar, V. T., Pereira, M. P., Minuzzo, L., Timerman, A., & Avezum, Á. (2011). *Comparison between cardiac troponin I and CK-MB mass in acute coronary syndrome without ST elevation*. *Arquivos Brasileiros de Cardiologia*, 96(3), 179–187. <https://doi.org/10.1590/S0066-782X2011005000016>
- Fox, K. A. A., Bassand, J.-P., Mehta, S. R., Wallentin, L., Theroux, P., Piegas, L. S., Valentin, V., Moccetti, T., Chrolavicius, S., Afzal, R., & Yusuf, S. (2007). *Influence of Renal Function on the Efficacy and Safety of Fondaparinux Relative to Enoxaparin in Non – ST-Segment Elevation*. *Annals of Internal Medicine* Article, 12.
- Guerra, F., & Capucci, A. (2018). *Serum potassium and acute coronary syndrome: In medio stat virtus*. *European Journal of Preventive Cardiology*, 25(6), 574–575. <https://doi.org/10.1177/2047487318759689>
- Harahap, U., & Margata, L. (2018). *The Significance of Troponin and Ck-Mb in Association with Q-Wave Myocardial Infarction*. *Indonesian Journal of Pharmaceutical and Clinical Research*, 1(1), 11–17. <https://doi.org/10.32734/idjpcr.v1i1.199>
- Jolly, S. S., Faxon, D. P., Fox, K. A. A., Afzal, R., Boden, W. E., Widimsky, P., Steg, P. G., Valentin, V., Budaj, A., Granger, C. B., Joyner, C. D., Chrolavicius, S., Yusuf, S., & Mehta, S. R. (2009). *Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients With Acute Coronary Syndromes Treated With Glycoprotein IIb/IIIa Inhibitors or Thienopyridines. Results From the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) Trial*. *Journal of the American College of Cardiology*, 54(5), 468–476. <https://doi.org/10.1016/j.jacc.2009.03.062>
- Joyner, C. D., Peters, R. J. G., Afzal, R., Chrolavicius, S., Franzosi, M. G., Flather, M., Budaj, A., & Bassand, J. (2009). *Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: Outcomes and treatment effect across different levels of risk*. *American Heart Journal*, 157(3), 502–508. <https://doi.org/10.1016/j.ahj.2008.10.028>
- Kementerian Kesehatan RI Badan Penelitian dan Pengembangan. (2018). Hasil

Utama Riset Kesehatan Dasar. *Kementrian Kesehatan Republik Indonesia*, 1–100.

- Kossovsky, M. P., Keller, P., & Gaspoz, J. (2012). *Fondaparinux versus enoxaparin in the management of acute coronary syndromes in Switzerland. March*, 1–6. <https://doi.org/10.4414/smw.2012.13536>
- Lei, W.-Y., Wang, J.-H., Wen, S.-H., Yi, C.-H., Hung, J.-S., Liu, T., Orr, W. C., & Chen, C.-L. (2014). *Risk of acute myocardial infarction in patients with gastro-esophageal reflux disease: A nationwide database study. Gastroenterology*, 146(5 SUPPL. 1), S-126. <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed12&NEWS=N&AN=71456133>
- Mehta, S. R., Granger, C. B., Eikelboom, J. W., Bassand, J. P., Wallentin, L., Faxon, D. P., Peters, R. J. G., Budaj, A., Afzal, R., Chrolavicius, S., Fox, K. A. A., & Yusuf, S. (2007). *Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. Results From the OASIS-5 Trial. Journal of the American College of Cardiology*, 50(18), 1742–1751. <https://doi.org/10.1016/j.jacc.2007.07.042>
- Okonkwo, U., Umoh, I., Henshaw, E., & Victor, A. (2017). *Prevalence of dyspeptic symptoms among patients on low-dose antiplatelet therapy. Nigerian Journal of Cardiology*, 14(2), 92. https://doi.org/10.4103/njc.njc_15_17
- PERKI. (2018). *Pedoman Tata Laksana Sindrom Koroner Akut*. Perhimpunan Dokter Spesialis Kardiovaskular Indonesia.
- Permsuwan, U., Pharmd, N. C., Pharmd, S. N., & Sukonthasarn, A. (2015). *Cost-Effectiveness Analysis of Fondaparinux vs Enoxaparin in Non-ST Elevation Acute Coronary Syndrome in. Heart, Lung and Circulation*, 1–9. <https://doi.org/10.1016/j.hlc.2015.02.018>
- Rapid, T., Service, R., & Cadth, W. (2015). *Fondaparinux versus Enoxaparin for Acute Coronary Syndrome: A Review of the Comparative Clinical Effectiveness and Cost-Effectiveness. September*.
- Rashid, M. H., Yaseen, G., Ghaffar, U., Khan, A. A., Kabir, A., Aisha, A., & Komel, A. (2020). *Prevalence of Acute Coronary Syndrome and Various Risk Factors in Acute Stroke Patients. Cureus*, 12(8). <https://doi.org/10.7759/cureus.9552>

- Roffi, M., Patrono, C., Collet, J. P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., Gencer, B., Hasenfuss, G., Kjeldsen, K., Lancellotti, P., Landmesser, U., Mehilli, J., Mukherjee, D., Storey, R. F., Windecker, S., ... Zamorano, J. L. (2016). *2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent st-segment elevation: Task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of . European Heart Journal, 37(3), 267–315.* <https://doi.org/10.1093/eurheartj/ehv320>
- Sculpher, M. J., Lozano-ortega, G., Sambrook, J., & Palmer, S. (2009). *Fondaparinux versus Enoxaparin in non – ST-elevation acute coronary syndromes : Short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial. American Heart Journal, 157(5), 845–852.* <https://doi.org/10.1016/j.ahj.2009.02.017>
- Soeiro, A. de M., e Silva, P. G. M. de B., Roque, E. A. de C., Bossa, A. S., César, M. C., Simões, S. A., Okada, M. Y., Leal, T. de C. A. T., Pedroti, F. C. M., & de Oliveira, M. T. (2016). *Fondaparinux versus enoxaparin – Which is the best anticoagulant for acute coronary syndrome? – Brazilian registry data. Arquivos Brasileiros de Cardiologia, 107(3), 239–244.* <https://doi.org/10.5935/abc.20160127>
- Sukmawan, Y. P., Idacahyati, K., & Firdaus, R. F. (2020). *Enoxaparin vs Fondaparinux in CK-MB Reduction. Jurnal Farmasi Indonesia, 17(2), 78–82.* <https://doi.org/10.31001/jfi.v17i2.810>
- ten Haaf, M. E., Bax, M., ten Berg, J. M., Brouwer, J., van't Hof, A. W., van der Schaaf, R. J., Stella, P. R., Tjon Joe Gin, R. M., Tonino, P. A., de Vries, A. G., Zijlstra, F., Boersma, E., & Appelman, Y. (2019). *Sex differences in characteristics and outcome in acute coronary syndrome patients in the Netherlands. Netherlands Heart Journal, 27(5), 263–271.* <https://doi.org/10.1007/s12471-019-1271-0>
- Valgimigli, M., Frigoli, E., Leonardi, S., Rothenbühler, M., Gagnor, A., Calabrò, P., Garducci, S., Rubartelli, P., Briguori, C., Andò, G., Repetto, A., Limbruno, U., Garbo, R., Sganzerla, P., Russo, F., Lupi, A., Cortese, B., Ausiello, A., Ierna, S., ... Vranckx, P. (2015). *Bivalirudin or unfractionated heparin in acute coronary syndromes. New England Journal of Medicine, 373(11), 997–1009.* <https://doi.org/10.1056/NEJMoa1507854>
- Washam, J. B., Herzog, C. A., Beitelshees, A. L., Cohen, M. G., Henry, T. D., Kapur, N. K., Mega, J. L., Menon, V., Page, R. L., & Newby, L. K. (2015). *Pharmacotherapy in chronic kidney disease patients presenting with acute coronary syndrome: A scientific statement from the American Heart Association. Circulation, 131(12), 1123–1149.* <https://doi.org/10.1161/CIR.0000000000000183>

- Yusuf, S., Mehta, S. R., Chrolavicius, S., Afzal, R., Pogue, J., Christopher, B., Budaj, A., Peters, J. G., Bassand, J., Wallentin, L., Joyner, C., Fox, K. A. A., & Clinic, M. (2006). *Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes. New England Journal of Medicine*, 354(14), 1464–1476. <https://doi.org/10.1056/nejmoa055443>
- Zhao, X. M., Gao, C. Y., Chu, Y. J., Ms, L. Y., Bs, X. Z. Y., Ms, W. K. X., Bs, W. Q. H., Bs, P. R. Z., & Ms, X. Y. L. (2015). *Fondaparinux vs . enoxaparin in patients with non-ST elevation acute coronary syndromes (NSTE-ACS) treated with percutaneous coronary intervention and tiro fi ban : an exploratory study in China*. 584–589. <https://doi.org/10.1111/jcpt.12315>
- Zhao, X., Yang, X., Ji, S., Wang, X., Wang, L., Gu, C., & Ren, L. (2016). *Efficacy and safety of fondaparinux versus enoxaparin in patients undergoing percutaneous coronary intervention treated with the glycoprotein IIb / IIIa inhibitor tirofiban. Military Medical Research*, 1–7. <https://doi.org/10.1186/s40779-016-0081-6>